Complete, Durable Remission of Advanced Hepatocellular Carcinoma under Treatment with Viscum album Extracts: A Case Report

• Published in: Complementary medicine research Vol. 29; no. 6; p. 483
• Main Authors: Orange, Maurice, Poidimani, Nicoletta, Crosignani, Andrea, Werthmann, Paul G, Bertotto, Corrado
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2022
• Subjects: Carcinoma, Hepatocellular - drug therapy; Female; Humans; Liver Neoplasms - drug therapy; Middle Aged; Neoplasm Recurrence, Local; Plant Extracts - therapeutic use; Quality of Life; Viscum album; L-Ornithine-L-aspartate; Hepatocellular carcinoma; Complete remission; Hepatitis C; Viscum album
• ISSN: 2504-2106
• DOI: 10.1159/000525409

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths. Early-stage disease is treated with curative intent, but most patients present with advanced HCC, which carries a poor prognosis. Viscum album extracts (VAE) are used by cancer patients as an adjunct treatment or palliation. A 51-year-old female presented with relapsing multifocal HCC. She declined palliative treatment and commenced intravenous VAE treatment in conjunction with intravenous hepato-protective L-ornithine-L-aspartate (LOLA). She experienced a significant improvement of life-quality and performance status. After 3 months, a significant regression was noted on computerized tomography, and α-fetoprotein was in normal range. Imaging 11 months later confirmed a complete regression. The VAE and LOLA treatment continues to date. The patient had no other cancer-directed therapy. The regression is sustained for more than 5 years at publication, confirmed by regular imaging and serology. The patient is experiencing an unrestricted quality of life. Complete regression of advanced HCC is rare. Responses of HCC to VAE treatment have been reported before. However, this is the first documented case with a complete and durable regression of an HCC under treatment with VAE. Further studies should evaluate VAE treatment in HCC, especially when administered in forms as reported here.